

Control of the leishmaniases

Report of a meeting of the
WHO Expert Committee on the
Control of Leishmaniases,
Geneva, 22–26 March 2010



**World Health
Organization**

CONTROL OF THE LEISHMANIASES

Report of a meeting of the
WHO Expert Committee on the
Control of Leishmaniases,
Geneva, 22–26 March 2010



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data:

Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis, Geneva, 22-26 March 2010.

(WHO technical report series ; no. 949)

1. Leishmaniasis - prevention and control. 2. Leishmaniasis - parasitology. 3. Leishmaniasis - pathology. 4. Leishmaniasis - diagnosis. 5. Leishmaniasis, Cutaneous. I. WHO Expert Committee on the Control of the Leishmaniasis. II. World Health Organization. III. Series.

ISBN 978 92 4 120949 6

(NLM classification: WR 350)

ISSN 0512-3054

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Switzerland
published 2010

Table of contents

Members of the Expert Committee, temporary advisers, secretariat	vii
Acronyms and abbreviations	xi
Introduction	xii
1. History	1
2. Leishmaniases in humans	5
2.1 Clinical forms	5
2.1.1 Old World visceral leishmaniasis	5
2.1.2 Old World cutaneous leishmaniasis	7
2.1.3 Old World mucosal leishmaniasis	9
2.1.4 Old World diffuse cutaneous leishmaniasis	9
2.1.5 New World visceral leishmaniasis	9
2.1.6 New World cutaneous leishmaniasis	10
2.1.7 New World mucocutaneous leishmaniasis	10
2.1.8 New World diffuse cutaneous leishmaniasis	11
2.1.9 Disseminated cutaneous leishmaniasis	11
2.1.10 Post-kala-azar dermal leishmaniasis	11
2.1.11 <i>Leishmania</i> and HIV coinfection	12
2.2 Pathology	12
2.2.1 General pathology	12
2.2.2 Visceral leishmaniasis	13
2.2.3 Post-kala-azar dermal leishmaniasis	14
2.2.4 Uncomplicated cutaneous leishmaniasis	14
2.2.5 Disseminated cutaneous leishmaniasis	15
2.2.6 Leishmaniasis recidivans	16
2.2.7 Diffuse cutaneous leishmaniasis	16
2.2.8 Mucocutaneous leishmaniasis	16
2.3 Parasitology	17
2.3.1 Identification criteria	18
2.3.2 Reference strains	18
2.3.3 Identification methods	20
2.3.4 Taxonomy	21
2.4 Reservoir hosts	22
2.4.1 Definition	22
2.4.2 General aspects of reservoir capacity	22
2.4.3 Incrimination of reservoir hosts	23
2.4.4 Humans as reservoir hosts	24
2.4.5 Domestic and peridomestic reservoir hosts	24
2.4.6 Wild reservoir hosts of the Old World	25
2.4.7 Wild reservoir hosts of the New World	26
2.5 Vectors	27
2.5.1 Taxonomy	27
2.5.2 Identification criteria	28
2.5.3 Biology	29

2.5.4	Incrimination of vectors	33
2.5.5	Vector competence	35
2.6	Epidemiological aspects	36
2.6.1	Major foci and human behaviour	37
2.6.2	Socioeconomic factors	40
2.6.3	Malnutrition	40
2.6.4	Population movement	40
2.6.5	Environmental changes	41
2.6.6	Climate change	42
2.6.7	Periodic fluctuations in incidence of disease	43
2.6.8	Epidemiological research and mathematical models	44
2.6.9	Geographical information systems	45
2.6.10	Epidemiological surveys of visceral leishmaniasis	46
3.	Control	49
3.1	Diagnosis	49
3.1.1	Visceral leishmaniasis	49
3.1.2	Cutaneous leishmaniasis	52
3.1.3	Mucocutaneous leishmaniasis	53
3.1.4	Post-kala-azar dermal leishmaniasis	53
3.1.5	Coinfection with <i>Leishmania</i> and HIV	53
3.2	Treatment and vaccines	54
3.2.1	General considerations	54
3.2.2	Antileishmanial medicines	55
3.2.3	Treatment options	57
3.2.4	Special situations	65
3.2.5	Prophylactic leishmaniasis vaccines	71
3.2.6	Immunochemotherapy and therapeutic vaccines	73
3.3	Detection	73
3.3.1	Passive case detection	73
3.3.2	Active case detection	74
3.4	Control of reservoir hosts	75
3.4.1	Humans as reservoir hosts	75
3.4.2	Canine reservoir hosts	76
3.4.3	Wild animal reservoir hosts of Old World cutaneous leishmaniasis	77
3.4.4	Wild animal reservoir hosts of New World cutaneous leishmaniasis	78
3.5	Vector control	79
3.5.1	General considerations	79
3.5.2	Methods	80
3.5.3	Entomological monitoring and evaluation of vector control operations	83
3.6	Epidemic response	83
3.6.1	Rapid assessment	84
3.6.2	Epidemic preparedness	85
3.6.3	Outbreak response	85
3.7	Socioeconomic aspects of leishmaniasis control	86
3.7.1	Social determinants of risk	87
3.7.2	Cost-effectiveness of control measures	88

3.7.3	Access to medicines and diagnostics	89
3.7.4	Public–private partnerships	90
4.	Burden of leishmaniasis	91
4.1	Geographical distribution by country	91
4.2	Estimated burden	104
5.	Control strategies by nosogeographical entity	107
5.1	Visceral leishmaniasis caused by <i>L. donovani</i> and <i>L. infantum</i> (<i>L. chagasi</i>)	107
5.1.1	Visceral leishmaniasis caused by <i>L. donovani</i> on the Indian subcontinent	107
5.1.2	Visceral leishmaniasis in East Africa and the south-west Arabian peninsula caused by <i>L. donovani</i> and <i>L. infantum</i>	109
5.1.3	Visceral leishmaniasis caused by <i>L. donovani</i> in other places	110
5.1.4	Foci of visceral leishmaniasis caused by <i>L. infantum</i> with known or assumed canine reservoir hosts	110
5.2	Anthroponotic cutaneous leishmaniasis caused by <i>L. tropica</i>	113
5.3	Sporadic cutaneous leishmaniasis caused by <i>L. tropica</i> and related species	114
5.4	Zoonotic cutaneous leishmaniasis caused by <i>L. major</i>	116
5.5	Zoonotic cutaneous leishmaniasis in the East African highlands caused by <i>L. aethiopica</i>	118
5.6	Cutaneous leishmaniasis caused by <i>L. peruviana</i>	119
5.7	Cutaneous leishmaniasis caused by <i>L. guyanensis</i>	121
5.8	Cutaneous and mucocutaneous leishmaniasis caused by <i>L. panamensis</i>	122
5.9	Cutaneous and mucocutaneous leishmaniasis caused by <i>L. braziliensis</i>	123
5.10	Cutaneous leishmaniasis caused by <i>L. mexicana</i> and related species	124
5.11	Cutaneous leishmaniasis caused by <i>L. infantum</i>	125
5.12	Cutaneous leishmaniasis caused by other New World species	125
6.	Organization of control	127
6.1	Control of leishmaniasis as part of primary health care	128
6.1.1	Community participation	129
6.1.2	Social mobilization and communication	129
6.2	Definition of national plans	129
6.2.1	Purpose and implementation of national control programmes	130
6.2.2	Collection of epidemiological data	133
6.2.3	Definition of control strategies and activities	133
6.2.4	Intersectoral coordination	133
6.2.5	Formal adoption of the national control strategy or plan	133
6.3	Surveillance	134
6.4	Pharmacovigilance	134

6.5	Monitoring and evaluation	136
7.	International coordination	139
7.1	Reporting	139
7.2	Technical partners	139
7.3	Intercountry programmes for advocacy and awareness-raising	140
7.4	International standards	141
8.	Health education and training	143
8.1	Health education	143
8.2	Training	144
9.	Research	149
9.1	Field research	149
9.2	Laboratory research	150
9.3	Drug and vaccine research and development	150
9.3.1	What products are needed?	150
9.3.2	Challenges to the development and use of antileishmanial treatment	151
9.3.3	Input of other approaches	152
10.	Recommendations	153
Annex 1.	Labelling of <i>Leishmania</i> isolates, identification centres and sources of standards	155
Annex 2.	Methods for isolation and cryopreservation of <i>Leishmania</i>	165
Annex 3.	WHO recommended case definitions	175
Annex 4.	Procedures for splenic aspiration and grading of parasites	177
Annex 5.	Performance of the rK39 rapid diagnostic test	181
Annex 6.	Costs of medicines in current use for the treatment of leishmaniases	185

Members of the Expert Committee, temporary advisers, secretariat

Members¹

Professor Richard W. Ashford, former Professor of Parasite and Vector Biology at Liverpool School of Tropical Medicine, United Kingdom

Dr Caryn Bern (*Rapporteur*), Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Professor Marleen Boelaert, Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium

Emeritus Professor Anthony Bryceson (*Chairman*), Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom

Dr François Chappuis, Division of International and Humanitarian Medicine, Geneva University Hospitals, Switzerland

Professor Simon Croft, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom

Professor Jean-Pierre Dedet, Université Montpellier 1 and National Reference Centre for *Leishmania*, Montpellier, France

Dr Philippe Desjeux, Institute for One World Health, San Francisco, CA, USA

预览已结束，完整报告链接和二维码

<https://www.yunbaogao.cn/report/index/report?reportId>